Distinct clinical trials, such as JULIET (Tisagenlecleucel in r/r DLBCL) and ZUMA-1 (Axicabtagene ciloleucel in r/r DLBCL, Primary Mediastinal B-Cell Lymphoma, or transformed FL), have investigated the overall response rates (ORRs) following CD19-CAR T cell therapy, which were, respectively, 52% (41–62, 95% IC) and 82% (73–89, 95% IC) [6,7,8]. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.